Overview

Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients

Status:
Completed

Trial end date:
2010-04-01

Target enrollment:
0

Participant gender:
All

Summary

A new immunosuppressive drug, based on the inhibition of an important enzyme in the immune system called JAK3, is being developed by Pfizer to prevent transplant rejection. In this research study, a JAK3 inhibitor or cyclosporine will be given to new kidney transplant patients for 12 months. Patients will be assigned to one of three treatment groups after receiving a kidney transplant. Two of the treatment groups will receive 2 different dosing regimens of the JAK3 inhibitor that will be taken by mouth. The third treatment group will be a standard-of-care control arm. Patients will continue to take the assigned study medication for 12 months as well as other standard transplant medications such as prednisone.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Pfizer

Treatments:

Cyclosporine
Cyclosporins
Tofacitinib

Criteria

Inclusion Criteria:

- Recipient of a first-time kidney transplant

- Between the ages of 18 and 70 years, inclusive

Exclusion Criteria:

- Recipient of any non-kidney transplant